Table 1.
Maternal and neonatal clinical characteristics for twin-to-twin transfusion syndrome cases evaluated during the first year of the COVID-19 pandemic (2020) and the same period of the previous year
| Characteristic | 2019 (n=55) | 2020 (n=54) | P valuea |
|---|---|---|---|
| Maternal age (y) | 29.9 (6.0) | 29.3 (5.5) | .64 |
| BMI (kg/m2) | 26.0 (5.4) | 27.9 (6.4) | .11 |
| Primiparity | 38.2 | 42.6 | .64 |
| Fortnightly antenatal visits | 52.7 | 29.6 | .01 |
| TTTS staging | |||
| I | 30.9 | 20.4 | .21 |
| II | 32.7 | 25.9 | .44 |
| III | 20.0 | 27.8 | .34 |
| IV | 14.5 | 18.5 | .58 |
| V | 1.8 | 7.4 | .16 |
| Late TTTS stage (III–V) | 36.4 | 53.7 | .07 |
| Refused fetoscopic laser therapy | 5.5 | 7.4 | .68 |
| TTTS complications precluding fetoscopy | 3.6 | 18.5 | .01 |
| TTTS stage V | 1.8 | 7.4 | .16 |
| PPROM before laser | 0.0 | 3.7 | .15 |
| Cervical dilatation | 1.8 | 5.6 | .30 |
| Fetoscopic laser therapy | 90.9 | 75.9 | .03 |
| Short cervix at diagnosis | 10.9 | 25.9 | .04 |
| GA at delivery (wk) | 29.9 (5.8) | 29.2 (10.3) | .68 |
| Preterm delivery<32 wk | 43.6 | 45.1 | .88 |
| Overall survival | |||
| 1 twin | 80.0 | 56.9 | .01 |
| 2 twins | 56.4 | 39.2 | .08 |
Data are presented as mean (standard deviation) or percentage, unless otherwise indicated.
BMI, body mass index; GA, gestational age; PPROM, preterm premature rupture of membranes; TTTS, twin-to-twin transfusion syndrome.
a
The Student t test for independent samples or the Pearson chi-squared test was used.
López-Briones. Twin-to-twin transfusion syndrome and COVID-19. Am J Obstet Gynecol Glob Rep 2022.